Engineered repressors are potent inhibitors of androgen receptor activity

Prostate cancer growth is dependent upon the Androgen Receptor (AR) pathway, hence therapies for this disease often target this signalling axis. Such therapies are successful in the majority of patients but invariably fail after a median of 2 years and tumours progress to a castrate resistant stage...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Brooke, Greg N., Powell, Sue M., Lavery, Derek N., Waxman, Jonathan, Buluwela, Laki, Ali, Simak, Bevan, Charlotte L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2014
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4011597/
https://ncbi.nlm.nih.gov/pubmed/24659630
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak